OOIR: Observatory of International Research

Papers

(The H4-Index of mAbs is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Antibodies to watch in 2022	235
Antibodies to watch in 2021	234
Antibodies to watch in 2023	110
Targeting cancer with antibody-drug conjugates: Promises and challenges	85
BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning	56
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy	52
Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies	51
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro	48
Developments and opportunities in continuous biopharmaceutical manufacturing	40
In silico proof of principle of machine learning-based antibody design at unconstrained scale	37
Fc galactosylation follows consecutive reaction kinetics and enhances immunoglobulin G hexamerization for complement activation	36
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins	35
Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics	35
Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns	33
A computational method for immune repertoire mining that identifies novel binders from different clonotypes, demonstrated by identifying anti-pertussis toxoid antibodies	32
Coming together at the hinges: Therapeutic prospects of IgG3	32
Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods	32
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors	31
One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics	30
Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development	29
Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics	29
Calculation of therapeutic antibody viscosity with coarse-grained models, hydrodynamic calculations and machine learning-based parameters	27
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	26
Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies	26
Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries	25

Ab-Ligity: identifying sequence-dissimilar antibodies that bind to the same epitope	25
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays	25